Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer

Journal of the National Cancer Institute

Volumn 90, Issue 20, 1998, Pages 1563-1568

  Mitsudomi, Tetsuya ^a   Suzuki, Susumu ^b   Yatabe, Yasushi ^a   Nishio, Masayuki ^a   Kuwabara, Masaki ^a   Gotoh, Kunihiko ^a   Hatooka, Shunzo ^a   Shinoda, Masayuki ^a   Suyama, Motokazu ^a   Ogawa, Makoto ^a   Takahashi, Toshitada ^a   Ariyoshi, Yutaka ^c   Takahashi, Takashi ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b Medical & Biological Laboratories Co Ltd   (Japan)

^c Dept of Orthopaedic Surgery

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; PEPTIDE; PROTEIN P53;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; HUMAN; IMMUNOBLOTTING; INCIDENCE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM; TUMOR SUPPRESSOR GENE;

EID: 0032556216     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.20.1563     Document Type: Article

References (25)

1. Minna JD, Sekido Y, Fong KW, Gazdar AF. Molecular biology of lung cancer, cancer of the lung. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology Philadelphia: Lippincott, 1997; p. 849-57.
2. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-55.
3. Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild CP, et al. p53 antibodies in patients with various types of cancer: Assay, identification, and characterization. Clin Cancer Res 1995;1:1463-9.
4. Soussi T. The humoral response to the tumor-suppressor gene product p53 in human cancer: implications for diagnosis and therapy. Immunol Today 1996;17:354-6.
5. Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Tredaniel J, Hirsch A, et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution of primary structure and exposure on protein surface. Cancer Res 1993;53:5872-6.
6. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992;52:4168-74.
7. Wild CP, Ridanpaa M, Anttila S, Lubin R, Soussi T, Huggafvel-Pursiainen K, et al. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int J Cancer 1995;64:176-81.
8. Schlichtholz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T. Analysis of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 1994;69:809-16.
9. Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, Takagi Y, et al. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 1996;14:497-502.
10. Nishio M, Koshikawa T, Yatabe Y, Kuroishi T, Suyama M, Nagatake M, et al. Prognostic significance of cyclin Dl and Rb expression in combination with p53 abnormalities in primary, resected non-small cell lung cancer. Clin Cancer Res 1997;3:1051-8.
11. Mountain CF. A new international staging system for lung cancer. Chest 1986;89(4 Suppl): 225s-233s.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50: 163-70.
14. Cox DR. Regression models and life tables. J R Stat Soc Series B 1972;34:187-220.
15. Rosenfeld MR, Malats N, Schramm L, Graus F, Cardenal F, Vinolas N, et al. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Natl Cancer Inst 1997; 89:381-5.
16. von Brevern MC, Hollstein MC, Cawley HM, De Benedetti VM, Bennett WP, Liang L, et al. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res 1996;56:4917-21.
17. Lubin R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Cazals D, et al. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995;1:701-2.
18. Trivers GE, DeBenedetti VMG, Cawley HL, Caron G, Harrington AM, Bennett WP, et al. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 1996;2:1767-75.
19. Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Nakanishi R, et al. p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effect on patient survival. Ann Oncol 1995;6 Suppl 3:S9-13.
20. Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, et al. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 1995;13: 1893-903.
21. Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 1995;345:621-2.
22. Houbiers JG, van der Burg SH, van de Watering LM, Tollenaar RA, Brand A, van de Velde CJ, et al. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 1995;72:637-41.
23. Bourhis J, Lubin R, Roche B, Koscielny S, Bosq J, Dubois I, et al. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1966; 88:1228-33.
24. Tilkin AF, Lubin R, Soussi T, Lazar V, Janin N, Mathieu MC, et al. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol 1995;25:1765-9.
25. Yanuck M, Carbone DP, Pendleton CD, Tsukui T, Winter SF, Minna SF, et al. A mutant p53 tumor suppressor protein is a target tor peptide-induced CD8+ cytotoxic T-cells. Cancer Res 1993;53:3257-61.